A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
Condition: Relapsing Remitting Multiple SclerosisInterventions: Drug: Glatiramer acetate (GA); Other: PlaceboSponsor: Teva Pharmaceutical IndustriesActive, not recruiting - verified January 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials